BioCentury
ARTICLE | Clinical News

Rifaximin soluble solid dispersion: Phase II started

September 2, 2013 7:00 AM UTC

Salix disclosed in its 2Q13 earnings that in June it began a double-blind, U.S. Phase II trial to evaluate once-daily rifaximin SSD tablets for 24 weeks in about 420 patients. Patients will receive 40 or 80 mg immediate-release rifaximin; 40 or 80 mg sustained extended-release rifaximin; 80 mg immediate-release rifaximin plus 80 mg sustained extended-release rifaximin; or placebo. ...